Aktie EXALENZ BIOSCIENCE LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Exalenz Bioscience Ltd. TEL AVIV STOCK EXCHANGE

Aktien

IL0011048688

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others.
Meridian Bioscience : Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million.
Exalenz Bioscience Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019
Exalenz Bioscience Receives Approval for Commercial Marketing in China for Its Breathid® HP Lab System
Exalenz Bioscience Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018
Exalenz Bioscience Ltd Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2018
Exalenz Bioscience Ltd. Announces BreathID®13C-methacetin Breath Test
Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer
Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients
Exalenz Bioscience Ltd Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017; Provides Earnings Guidance for the Year 2018 and Revenue Guidance for the Year 2019
Exalenz Bioscience Announces Positive Clinical Trial Results for the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients
Exalenz Bioscience Ltd Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection
Exalenz Bioscience Plans For Nasdaq IPO
Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to Use BreathID to Monitor Patients with Cirrhosis Associated with NASH
Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02
Exalenz Bioscience Ltd Launches Clinical Study for Breath-Based Detection of Primary Liver Cancer
Exalenz Bioscience Launches Additional Clinical Study of Breath-Based Diagnostic Test
Exalenz Bioscience Ltd. Auditor Raises 'Going Concern' Doubt
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0Q7UQ Aktie
  4. Aktie
  5. Nachrichten Exalenz Bioscience Ltd.
  6. Andere Sprachen